Adult Malignant Glioma Therapeutics Market Size, Share and Industry Analysis Product By Therapy (Chemotherapy, Radiotherapy, Targeted therapy) By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma) By End User, and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)

  • TBI558210
  • August 25, 2020
  • Global
  • 132 pages
  • ROIF Expert
                                          

We have updated Adult Malignant Glioma Therapeutics Market with respect to COVID-19 Business Impact. Inquire before buying This report focuses on the Adult Malignant Glioma Therapeutics market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Adult Malignant Glioma Therapeutics market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.

Global Adult Malignant Glioma Therapeutics Market: Segment Analysis

The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.

Global Adult Malignant Glioma Therapeutics Market: Regional Analysis

The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.

Global Adult Malignant Glioma Therapeutics Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.

List of Companies Profiled

  • Merck & Co., Inc.
  • Hoffmann-La Roche Ltd
  • Arbor Pharmaceuticals
  • Pfizer Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Novocure

Report Coverage

Glioma is a type of tumor that arises in the glial cells of the brain or spine. These comprise of around 30-40% of the primary central nervous system tumors and about 70-80% of all the malignant brain tumors. Unmet medical needs, increase in the global prevalence of the disease, and growing affordability for advanced therapies such as targeted therapies are likely to augment the demand for products designed for the treatment of adult malignant glioma. The glioblastoma multiforme is the most common form of the glioma occurring in the adult population. It is the deadliest form of the disease requiring high end of medical care. Despite the continuous increase in the global patient population of glioma, the incidence is still less and the products approved for the treatment comes under the orphan category. The high cost of product development and less patient population are the major factors hindering the entry of new players in the market. The report provides qualitative and quantitative insights on adult malignant glioma therapeutics and detailed analysis of market size and growth rate for all possible segments in the market. The market is segmented by therapy, disease type, the end-user, and region. In terms of therapy, the global adult malignant glioma therapeutics market segmented into chemotherapy, radiation therapy, targeted therapy, and others. In terms of disease type, the market is studied for segments such as glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, and others. Various end-users covered under the report are hospitals, specialty clinics, cancer and radiation therapy centers, others. Geographically, the market is segmented into four major regions, which are North America, Europe, Asia Pacific, and the rest of the World. The regions are further categorized into countries. Along with this, the report provides elaborative analysis of the adult malignant glioma therapeutics market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of glioma by key countries, an overview of technological advancements in the glioma therapy, recent industry developments such as mergers & acquisitions, and pipeline analysis.

SEGMENTATION

By Therapy

  • Chemotherapy
  • Radiotherapy
  • Targeted therapy
  • Others

By Disease

  • Glioblastoma Multiforme
  • Anaplastic Astrocytoma
  • Anaplastic Oligodendroglioma
  • MX Others

By End User

  • Hospitals
  • Specialty Clinics
  • Cancer and Radiation Therapy Centers
  • Others

By Geography

  • North America (USA and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Rest of the World
Key Industry Developments

In May 2019,

The Institute of Cancer Research, London, announced a prototype treatment that targets a genetic weakness in the brain cancer

In April 2019,

Leica Microsystems received DeNovo clearance from the U.S. Food and Drug Administration (FDA) to market its FL400 surgical microscope filter

In December 2018,

Zai Lab announced the launch of Optune, (Tumor Treating Fields or TTFields) in Hong Kong for the treatment of glioblastoma multiforme (GBM).  

Table of Content
Chapter 1. Methodology and Scope 
1.1. Research Methodology 
1.2. Research Scope & Assumptions 
1.3. List of Data Sources
Chapter 2. Executive Summary
Chapter 3. Adult Malignant Glioma Therapeutics Market
3.1. Market Segmentation 
3.2. Market Size and Growth Prospects, 2019 - 2029 
3.3. Value Chain Analysis 
3.4. Market Dynamics 
3.4.1. Market driver analysis 
3.4.2. Market restraint analysis
Chapter 4. Market Size by Application
4.1 Adult Malignant Glioma Therapeutics Market Consumption by Application (2015-2020) 
4.2 Adult Malignant Glioma Therapeutics Market Consumption by Application (2020-2029) 

|  read more...

Request a sample

Fill below form to request a sample

Enquiry

Please fill this form to enquire before buying

Discount

You can request for discount regarding the report by using below form